TRAF2 sirna

TRAF2 siRNA (Mouse)

Cat. Num. AAA8211873

• Gene Names: Traf2; AI325259
• Reactivity: Mouse
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: TRAF2; TRAF2 siRNA (Mouse); TNF receptor-associated factor 2; E3 ubiquitin-protein ligase TRAF2; TRAF2 sirna

• Host: Synthetic
• Reactivity: Mouse
• Specificity: TRAF2 siRNA (Mouse) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 508

• Applicable Applications for TRAF2 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of mouse TRAF2 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for TRAF2 sirna

siRNA to inhibit TRAF2 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 594150400
• NCBI GeneID: 22030
• NCBI Accession #: NP_001277342.1
• NCBI GenBank Nucleotide #: NM_001290413.1
• UniProt Accession #: P39429; O54896; A2AJA3
• Molecular Weight: 56,757 Da
• NCBI Official Full Name: TNF receptor-associated factor 2 isoform a
• NCBI Official Synonym Full Names: TNF receptor-associated factor 2
• NCBI Official Symbol: Traf2
• NCBI Official Synonym Symbols: AI325259
• NCBI Protein Information: TNF receptor-associated factor 2
• UniProt Protein Name: TNF receptor-associated factor 2
• Protein Family: TNF receptor-associated factor
• UniProt Gene Name: Traf2
• UniProt Entry Name: TRAF2_MOUSE

Uniprot Description

TRAF2: Regulates activation of NF-kappa-B and JNK and plays a central role in the regulation of cell survival and apoptosis. Required for normal antibody isotype switching from IgM to IgG. Has E3 ubiquitin-protein ligase activity and promotes 'Lys-63'- linked ubiquitination of target proteins, such as BIRC3, RIPK1 and TICAM1. Is an essential constituent of several E3 ubiquitin- protein ligase complexes, where it promotes the ubiquitination of target proteins by bringing them into contact with other E3 ubiquitin ligases. Regulates BIRC2 and BIRC3 protein levels by inhibiting their autoubiquitination and subsequent degradation; this does not depend on the TRAF2 RING-type zinc finger domain. Homotrimer, and heterotrimer with TRAF1 and TRAF3 (via TRAF domain). The domain containing the RING-type and the first TRAF-type zinc finger can also form homodimers (in vitro). Interacts with TNFRSF1B/TNFR2, TNFRSF4, TNFRSF5/CD40, CD27/TNFRSF7, TNFRSF8/CD30, TNFRSF9/CD137, TNFRSF11A/RANK, TNFRSF13B/TACI, TNFRSF14, TNFRSF16/NGFR, TNFRSF17/BCMA, TNFRSF18/AITR, TNFRSF19/TROY, TNFRSF19L/RELT, XEDAR, EDAR, Epstein-Barr virus BNFL1/LMP-1 and IL15RA. Interacts with CDK9, CSK, MAP3K1, MAP3K5, MAP3K11, MAP3K14, MAP4K2, RIPK1, RIPK2, TNIK, TBK1, SPHK1, TRADD, TRAFD1, TRAIP, TANK/ITRAF, TNFAIP3, TDP2, MAVS/IPS1, TICAM1 and TRPC4AP. Interacts with CASP8AP2, NFATC2IP, PEG3 and HIVEP3. Interacts with BIRC2 and BIRC3 N- terminus; a single BIRC2 or BIRC3 molecule interacts with a heterotrimer formed by TRAF1 and TRAF2, or a TRAF2 homotrimer. Identified in a complex composed of TRAF2, TRAF3, BIRC2 and BIRC3. Interaction with BIRC2 and/or BIRC3 is essential for degradation of NFKBIA and activation of NF-kappa-B. Interacts with CYLD, USP48, DAB2IP, IKKA and IKKB. Identified in a complex with TNFRSF1A, RIPK1 and IKKB. Interacts (via 'Lys-63'-linked polyubiquitin chains) with TAB2 and TAB3. Interacts with ERN1 and TAOK3. Interaction with TAOK3 is facilitated under ER stress conditions, such as treatment with tunicamycin, and may promote TRAF2 phosphorylation. Has very low E3 ubiquitin ligase activity in the absence of sphingosine-1-phosphate. E3 ubiquitin ligase activity is strongly activated by cytoplasmic sphingosine-1- phosphate. Belongs to the TNF receptor-associated factor family. A subfamily. 4 isoforms of the human protein are produced by alternative splicing.

Protein type: Autophagy; Ubiquitin ligase; Ubiquitin conjugating system; Ligase; EC 6.3.2.-

Cellular Component: internal side of plasma membrane; protein complex; cytoplasm; vesicle membrane; cell cortex; cytosol; ubiquitin ligase complex; lipid raft

Molecular Function: sphingolipid binding; identical protein binding; zinc ion binding; coenzyme F420-2 alpha-glutamyl ligase activity; metal ion binding; CD40 receptor binding; ribosomal S6-glutamic acid ligase activity; ubiquitin-protein ligase activity; mitogen-activated protein kinase kinase kinase binding; protein phosphatase binding; tumor necrosis factor receptor binding; protein binding; enzyme binding; UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-D-alanine ligase activity; thioesterase binding; ubiquitin protein ligase binding; protein complex binding; coenzyme F420-0 gamma-glutamyl ligase activity; lipid binding; ligase activity; receptor binding

Biological Process: positive regulation of JNK activity; protein autoubiquitination; apoptosis; protein heterooligomerization; activation of NF-kappaB-inducing kinase; positive regulation of T cell cytokine production; signal transduction; regulation of JNK cascade; activation of NF-kappaB transcription factor; regulation of apoptosis; cellular protein complex assembly; tumor necrosis factor-mediated signaling pathway; positive regulation of interleukin-2 production; protein complex assembly; positive regulation of transcription factor activity; protein catabolic process; regulation of immunoglobulin secretion; negative regulation of apoptosis